Status:
ACTIVE_NOT_RECRUITING
Outcomes of a Higher vs. Lower Hemodialysate Magnesium Concentration (Dial-Mag Canada)
Lead Sponsor:
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Collaborating Sponsors:
ICES
Canadian Institutes of Health Research (CIHR)
Conditions:
Kidney Diseases
End-Stage Kidney Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Many patients on hemodialysis have low levels of magnesium. Magnesium is needed to keep the heart, kidneys, and other organs working properly. Patients with low serum magnesium concentration have a hi...
Detailed Description
1. Statement of the health problem or issue In end-stage kidney disease, dialysis is needed to remove toxins and electrolytes that would otherwise accumulate in a patient's blood. The fluid used i...
Eligibility Criteria
Inclusion
- This pragmatic cluster randomized controlled trial has only two inclusion criteria:
- The hemodialysis centre, or a group of hemodialysis centers combined into one cluster, must care for at least 15 outpatients being treated with in-centre maintenance hemodialysis.
- The medical director of the hemodialysis centre must be willing for their centre to be randomized and to adopt the allocated dialysate Mg protocol as their standard solution for the duration of the trial.
Exclusion
- The centre, or group of hemodialysis centres cares for less than 15 patients being treated with conventional in-centre hemodialysis.
Key Trial Info
Start Date :
April 4 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
25000 Patients enrolled
Trial Details
Trial ID
NCT04079582
Start Date
April 4 2022
End Date
March 1 2026
Last Update
March 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
London Health Sciences Centre
London, Ontario, Canada, N6A5W9